Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin

36Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer is a leading cause of death in both developed and developing countries, and because of population growth and aging, it is a growing medical burden worldwide. With robust development in medicine, the use of stem cells has opened new treatment modalities in cancer therapy. In adult stem cells, mesenchymal stem cells (MSCs) are showing rising promise in cancer treatment due to their unique properties. Among different sources of MSCs, human amniotic fluid/membrane is an attractive and suitable reservoir. There are conflicting opinions about the role of human amniotic membrane/fluid mesenchymal stem cells (hAMSCS/hAFMSCs) in cancer, as some studies demonstrating the anticancer effects of these cells and others suggesting their progressive effects on cancer. This review focuses on recent findings about the role of hAMSCs/hAFMSCs in cancer treatment and summarizes the suppressing as well as promoting effects of these cells on cancer progression and underling mechanisms.

Cite

CITATION STYLE

APA

Jafari, A., Rezaei-Tavirani, M., Farhadihosseinabadi, B., Zali, H., & Niknejad, H. (2021, December 1). Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin. Stem Cell Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/s13287-021-02196-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free